Brain Tumor Surgery in Shanghai: What to Expect Before, During & After

A brain tumor diagnosis is among the most frightening a patient can receive. The brain's complexity, its role in governing every aspect of human function, and the technical demands of operating within it make neurosurgery one of the most specialized fields in medicine. Yet outcomes for many brain tumors — including some that were once considered inoperable — have improved substantially over the past two decades, driven by advances in neuroimaging, intraoperative technology, and multimodal treatment. Shanghai has developed a concentration of neurosurgical expertise that places it among Asia's leading centers for brain tumor management, with hospitals performing thousands of craniotomies annually using the most advanced techniques available.

Types of Brain Tumors

Brain tumors are broadly classified as primary (originating in the brain) or secondary (metastatic, spreading from cancer elsewhere in the body). Understanding the tumor type is fundamental to treatment planning.

Primary Brain Tumors

Primary brain tumors arise from the brain's own cells. The most clinically significant include:

• Gliomas: The most common primary brain tumors in adults, arising from glial cells (the supportive cells of the brain). Classified by the World Health Organization (WHO) into grades 1–4 based on histological and molecular features. The 2021 WHO classification now integrates molecular markers — particularly IDH mutation status, 1p/19q codeletion, and MGMT promoter methylation — as defining features alongside histology.
  • Glioblastoma (GBM, WHO grade 4): The most aggressive primary brain tumor. Median survival with standard treatment (surgery + temozolomide + radiotherapy) is approximately 15 months, though MGMT-methylated tumors respond better to chemotherapy and have improved outcomes.
  • IDH-mutant astrocytoma (WHO grade 2–3): Lower-grade gliomas with more favorable prognosis. IDH mutation confers better prognosis than IDH-wildtype tumors. Treatment involves surgery, often followed by radiotherapy and chemotherapy (PCV or temozolomide).
  • Oligodendroglioma (IDH-mutant, 1p/19q codeleted, WHO grade 2–3): Particularly chemosensitive. PCV chemotherapy combined with radiotherapy is the standard adjuvant approach.
• Meningiomas: Arise from the meninges (the membranes covering the brain and spinal cord). The most common primary intracranial tumor overall. Most are WHO grade 1 (benign) and grow slowly. Treatment depends on size, location, symptoms, and growth rate — options include observation, surgery, and stereotactic radiosurgery. Grade 2 (atypical) and grade 3 (anaplastic) meningiomas are more aggressive and require more aggressive treatment.
• Pituitary Adenomas: Benign tumors of the pituitary gland. Classified as functioning (secreting hormones — prolactinoma, acromegaly, Cushing’s disease) or non-functioning. Most are treated with transsphenoidal surgery (through the nose) or, for prolactinomas, with dopamine agonist medication. Endoscopic transsphenoidal surgery has largely replaced the traditional microscopic approach at high-volume centers.
• Acoustic Neuromas (Vestibular Schwannomas): Benign tumors of the vestibulocochlear nerve. Present with progressive unilateral hearing loss, tinnitus, and balance disturbance. Treatment options include observation, stereotactic radiosurgery (Gamma Knife), and microsurgical resection — the choice depending on tumor size, growth rate, hearing status, and patient preference.
• Ependymomas: Arise from ependymal cells lining the ventricles and central canal of the spinal cord. More common in children but occur in adults. Molecular classification (ZFTA fusion, YAP1 fusion, etc.) now guides prognosis and treatment.
• Primary CNS Lymphoma (PCNSL): A diffuse large B-cell lymphoma confined to the CNS. Treated primarily with high-dose methotrexate-based chemotherapy rather than surgery (biopsy only for diagnosis). Highly chemosensitive but prone to relapse.
• Craniopharyngiomas: Benign but locally aggressive tumors arising near the pituitary stalk. Cause significant endocrine, visual, and hypothalamic dysfunction. Management is complex and controversial — balancing extent of resection against functional preservation.

Brain Metastases

Brain metastases — cancer that has spread to the brain from a primary tumor elsewhere — are the most common intracranial tumors in adults, occurring in 10–30% of all cancer patients. The most common primary sources are lung cancer, breast cancer, melanoma, renal cell carcinoma, and colorectal cancer. Management has evolved significantly:

• For limited metastases (1–4 lesions), stereotactic radiosurgery (SRS) is the preferred approach, often avoiding whole-brain radiotherapy to preserve neurocognitive function.
• Surgical resection is indicated for large, symptomatic lesions causing mass effect, or when tissue diagnosis is needed.
• Systemic therapy (targeted agents, immunotherapy) increasingly controls brain metastases in molecularly selected patients — particularly EGFR-mutant lung cancer (osimertinib), ALK-rearranged lung cancer (alectinib, lorlatinib), HER2-positive breast cancer (tucatinib, trastuzumab deruxtecan), and melanoma (BRAF inhibitors, checkpoint inhibitors).

Diagnosis: Neuroimaging and Molecular Pathology

Accurate diagnosis of a brain tumor requires high-quality neuroimaging and, in most cases, tissue sampling for histological and molecular analysis.

MRI

MRI is the gold standard for brain tumor imaging. A comprehensive brain tumor MRI protocol includes:

• T1-weighted with gadolinium contrast: Identifies blood-brain barrier breakdown (enhancement), which correlates with higher-grade tumors and active disease.
• T2/FLAIR: Delineates tumor extent and surrounding edema. Low-grade gliomas are often non-enhancing but show T2/FLAIR signal abnormality.
• Diffusion-weighted imaging (DWI): Assesses cellularity and helps differentiate tumor from abscess.
• MR spectroscopy: Provides metabolic information (choline, NAA, lactate ratios) to characterize tumor biology and differentiate tumor from radiation necrosis.
• Perfusion MRI (DSC or DCE): Assesses tumor vascularity and blood volume — useful for grading and treatment response assessment.
• Functional MRI (fMRI): Maps eloquent cortex (language, motor areas) to guide surgical planning and minimize the risk of neurological deficits.
• Diffusion Tensor Imaging (DTI) / Tractography: Visualizes white matter tracts adjacent to the tumor, enabling surgeons to plan resection while preserving critical fiber pathways.

Shanghai's major neurosurgical centers have access to 3T MRI systems with full advanced imaging protocols. Pre-operative fMRI and DTI tractography are routinely performed for tumors in or near eloquent brain regions.

Molecular Pathology

The 2021 WHO classification of CNS tumors is heavily molecular. Following surgical resection or biopsy, tumor tissue is analyzed for:

• IDH1/IDH2 mutation status (immunohistochemistry and/or sequencing)
• 1p/19q codeletion (FISH)
• MGMT promoter methylation (pyrosequencing or methylation-specific PCR)
• TERT promoter mutation
• EGFR amplification, PTEN loss, chromosome 7 gain / chromosome 10 loss (for GBM classification)
• H3 K27M mutation (for diffuse midline gliomas)
• CDKN2A/B homozygous deletion (for grade designation in IDH-mutant astrocytomas)

Comprehensive molecular profiling is available at Shanghai's major neurosurgical pathology laboratories and is essential for accurate diagnosis, prognosis, and treatment planning.

Surgical Treatment: Craniotomy

Surgical resection — craniotomy — remains the cornerstone of treatment for most primary brain tumors and selected brain metastases. The goals of surgery are to obtain tissue for diagnosis, reduce tumor bulk (cytoreduction), relieve mass effect and intracranial pressure, and, where possible, achieve gross total resection (GTR).

The extent of resection is one of the strongest predictors of outcome in glioma surgery. Studies consistently show that GTR is associated with longer progression-free and overall survival compared to subtotal resection, even in high-grade gliomas. However, the benefit of aggressive resection must be balanced against the risk of neurological deficit — a calculation that requires both advanced intraoperative technology and experienced surgical judgment.

Key Intraoperative Technologies

Shanghai's leading neurosurgical centers employ a comprehensive suite of intraoperative technologies to maximize safe resection:

• Neuronavigation (Surgical Navigation Systems): Pre-operative MRI data is loaded into a navigation system that provides real-time 3D guidance during surgery, allowing the surgeon to precisely localize the tumor and plan the safest approach. Analogous to GPS for the brain.
• Intraoperative MRI (iMRI): An MRI scanner integrated into the operating room allows imaging during surgery to assess the extent of resection and identify residual tumor before closing. Available at select Shanghai centers. Studies show iMRI increases GTR rates by 20–30%.
• 5-Aminolevulinic Acid (5-ALA) Fluorescence-Guided Surgery: Patients take an oral dose of 5-ALA before surgery. The drug is metabolized preferentially by high-grade glioma cells into a fluorescent compound (protoporphyrin IX) that glows pink under blue-violet light. This allows surgeons to visually distinguish tumor from normal brain tissue in real time, significantly improving GTR rates for GBM.
• Intraoperative Ultrasound: Provides real-time imaging of tumor boundaries and residual disease during resection. Less expensive than iMRI but lower resolution.
• Intraoperative Neurophysiological Monitoring (IONM): Continuous monitoring of motor evoked potentials (MEPs), somatosensory evoked potentials (SSEPs), and electromyography (EMG) during surgery to detect and prevent injury to motor and sensory pathways.
• Awake Craniotomy: For tumors in or adjacent to eloquent cortex (language areas, primary motor cortex), surgery is performed with the patient awake and cooperative. The patient performs language or motor tasks while the surgeon uses cortical and subcortical stimulation mapping to identify and preserve functional areas. This technique allows more aggressive resection while minimizing the risk of permanent neurological deficit. Shanghai's neurosurgical teams at centers such as Huashan Hospital have extensive experience with awake craniotomy.
• Endoscopic Neurosurgery: For intraventricular tumors, pituitary adenomas, and skull base lesions, endoscopic approaches — particularly fully endoscopic transsphenoidal surgery — offer superior visualization and access through natural corridors without brain retraction.
• Laser Interstitial Thermal Therapy (LITT): A minimally invasive technique where a laser fiber is stereotactically inserted into the tumor and used to thermally ablate it under real-time MRI thermometry guidance. Useful for deep-seated, eloquently located, or recurrent tumors not amenable to open resection.

Radiation Therapy for Brain Tumors

Radiation therapy plays a central role in the adjuvant treatment of most malignant brain tumors and in the definitive management of some benign tumors.

• Conventional fractionated radiotherapy: Standard adjuvant treatment for GBM is 60 Gy in 30 fractions over 6 weeks (Stupp protocol), concurrent with temozolomide chemotherapy. For lower-grade gliomas, doses of 45–54 Gy are used.
• Hypofractionated radiotherapy: Shorter courses (e.g., 40 Gy in 15 fractions) are used for elderly or frail GBM patients to reduce treatment burden.
• Stereotactic Radiosurgery (SRS) — Gamma Knife / CyberKnife / Linac-based SRS: Single-fraction or hypofractionated high-dose radiation delivered with sub-millimeter precision. The treatment of choice for brain metastases (1–4 lesions), acoustic neuromas, meningiomas, and arteriovenous malformations (AVMs). Gamma Knife and CyberKnife systems are available at multiple Shanghai centers.
• Proton Beam Therapy: Delivers radiation with a Bragg peak, depositing maximum dose at the tumor while sparing surrounding brain tissue. Particularly valuable for pediatric brain tumors, skull base tumors, and tumors adjacent to critical structures. Available at select Shanghai facilities.
• Tumor Treating Fields (TTFields / Optune): A novel device-based therapy that delivers alternating electric fields to disrupt glioblastoma cell division. Approved as adjuvant therapy for GBM following the EF-14 trial, which demonstrated improved overall survival when added to maintenance temozolomide. Available in China at major neuro-oncology centers.

Chemotherapy and Systemic Therapy

• Temozolomide (TMZ): An oral alkylating agent that is the backbone of GBM chemotherapy. Administered concurrently with radiotherapy and then as maintenance therapy for 6 cycles. MGMT promoter methylation predicts benefit from TMZ.
• PCV chemotherapy (procarbazine, lomustine, vincristine): Standard adjuvant chemotherapy for oligodendroglioma and some IDH-mutant astrocytomas, based on RTOG 9802 and EORTC 26951 trial data.
• Bevacizumab: An anti-VEGF antibody used for recurrent GBM. Improves progression-free survival and reduces steroid requirements but has not demonstrated overall survival benefit in first-line treatment.
• High-dose methotrexate: The cornerstone of PCNSL treatment. Requires careful renal monitoring and leucovorin rescue.
• Targeted therapy for IDH-mutant gliomas: Vorasidenib (an IDH1/2 inhibitor) demonstrated significant improvement in progression-free survival in the INDIGO trial for grade 2 IDH-mutant gliomas and represents a new standard of care option.

Rehabilitation After Brain Tumor Surgery

Neurological rehabilitation is an essential component of brain tumor care. Depending on the tumor location and extent of surgery, patients may experience temporary or permanent deficits in motor function, speech, cognition, vision, or swallowing. A multidisciplinary rehabilitation team — comprising physiotherapists, occupational therapists, speech and language therapists, and neuropsychologists — works with patients to maximize functional recovery.

Most patients undergoing craniotomy for brain tumor are mobilized within 24–48 hours of surgery. Hospital stays typically range from 5 to 14 days depending on the complexity of the procedure and the patient’s neurological status. Inpatient neurorehabilitation for 2–4 weeks post-surgery is available at Shanghai facilities for patients requiring intensive rehabilitation before returning home.

What Medical Records Are Required

To facilitate a neurosurgical consultation in Shanghai, patients should prepare:

• MRI brain with contrast (full sequences including T1, T2, FLAIR, DWI — in DICOM format, ideally within 4–6 weeks)
• fMRI and DTI tractography (if previously performed)
• PET scan (if performed — FDG-PET or amino acid PET such as FET or MET)
• Pathology report and molecular profiling results (if biopsy or resection has already been performed)
• Operative report from any prior brain surgery
• Radiation therapy records (dose, fractionation, treatment fields) if prior radiotherapy received
• Chemotherapy records (agents, cycles, response)
• Neurological examination findings and functional status (KPS or ECOG score)
• Current medication list including corticosteroids and antiepileptic drugs
• Neuropsychological assessment (if performed)

Cost Reference

Indicative costs for brain tumor care in Shanghai:

• Neurosurgical consultation: USD 200–500
• MRI brain (full protocol with contrast): USD 400–900
• Stereotactic biopsy: USD 5,000–10,000
• Craniotomy for tumor resection (including hospital stay): USD 15,000–35,000
• Awake craniotomy: USD 20,000–40,000
• Endoscopic transsphenoidal surgery (pituitary): USD 10,000–20,000
• Gamma Knife / SRS (single session): USD 5,000–12,000
• Radiotherapy (full course, 30 fractions): USD 8,000–18,000
• Molecular pathology panel (IDH, MGMT, 1p/19q, etc.): USD 500–1,500

Comparable procedures in the United States typically cost 3–5 times these figures. A detailed estimate is provided after medical record review.

Frequently Asked Questions

Is every brain tumor operable?
Not all brain tumors require or are amenable to open surgery. Tumor location, size, relationship to eloquent structures, patient fitness, and tumor biology all influence operability. Some tumors — such as diffuse brainstem gliomas or PCNSL — are treated without resection. Others in previously considered inoperable locations can now be safely approached using awake craniotomy, laser ablation, or endoscopic techniques. A neurosurgical consultation will clarify what is feasible and appropriate for your specific tumor.

What is the risk of neurological deficit from brain surgery?
The risk depends heavily on tumor location. For tumors in non-eloquent regions, the risk of significant permanent deficit is low (<5%). For tumors adjacent to motor cortex, language areas, or deep structures, the risk is higher and must be weighed against the benefit of resection. Intraoperative monitoring, awake craniotomy, and neuronavigation significantly reduce — but do not eliminate — this risk.

How soon after surgery can I fly home?
For uncomplicated craniotomy with good neurological recovery, most neurosurgeons clear patients for long-haul travel at 4–6 weeks post-surgery, once wound healing is confirmed and any postoperative edema has resolved. Patients on corticosteroids or antiepileptic drugs require stable dosing before travel. Individual assessment is essential.

Can I access clinical trials for brain tumors in Shanghai?
Yes. Shanghai’s major neuro-oncology centers participate in international and China-specific clinical trials, including studies of novel IDH inhibitors, immunotherapy combinations, oncolytic viruses, and CAR-T cell therapy for brain tumors. Eligibility depends on tumor type, molecular profile, and prior treatment history.

Explore Your Options in Shanghai

If you or a family member has been diagnosed with a brain tumor and would like to explore surgical or oncological treatment in Shanghai, China Medical Concierge (CMCS) can coordinate your neurosurgical consultation, imaging review, hospital placement, and travel logistics. Contact us for a confidential initial discussion.